Methotrexate did not add skin cancer risk in patients with psoriasis receiving narrowband ultraviolet B phototherapy: a nationwide retrospective cohort study
Clinical and Experimental Dermatology · 2024
DOI: 10.1093/ced/llad424 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Clinical and Experimental Dermatology, 2024. Verfasst von Chun-Hsien Chao und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine Education. Hauptthemen laut MEDLINE: Methotrexate, Psoriasis, Skin Neoplasms, Ultraviolet Therapy. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology, Taiwan.
Abstract (Originalsprache)
Background
In the era of biologic therapy, phototherapy and methotrexate (MTX) are still commonly used for treatment in patients with moderate-to-severe psoriasis. However, the skin cancer risk following a combination of MTX and narrowband ultraviolet B (NB-UVB) has rarely been explored.
Objectives
To investigate whether MTX plus NB-UVB increases skin cancer risk in patients with psoriasis.
Methods
We conducted a retrospective cohort study of data in the Taiwan National Health Insurance Research Database from 1997 to 2013. Cumulative incidences and multivariate analysis were investigated using a competing risk regression model, comparing skin cancer risk between cohorts of people having combination therapy and those using NB-UVB alone, matched for relative confounders. We further conducted a sensitivity analysis for those receiving a higher MTX dose. Standardized incidence ratios (SIRs) were calculated for skin cancer risk.
Results
We enrolled 3203 participants in each cohort. No significant differences in skin cancers were noted between the two cohorts for the cumulative incidences (log-rank test, P = 0.28) and for the hazard ratio (HRs) [adjusted HR 0.50, 95% confidence interval (CI) 0.15–1.63, P = 0.247] in the competing risk regression model. There were also no significant differences between those receiving higher-dose MTX and UVB alone in the cumulative incidences of skin cancers (P = 0.23) and the HR (adjusted HR = 0.29, 95% CI 0.04–2.21, P = 0.23) in the multivariate analysis. There was no significant difference in the SIR between the two cohorts compared with the general population.
Conclusions
In the Taiwanese population, MTX does not increase skin cancer risk in patients with moderate-to-severe psoriasis receiving NB-UVB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medicine Education.
- Division of Translational Research.
- Institute of Biomedical Informatics and Research Center for Epidemic Prevention and.
- Faculty of Medicine and Institute of Clinical Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan.
- Department of Public Health, China Medical University, Taichung, Taiwan.
- National Institute of Cancer Research and Institute of Population Health Science, National Health Research Institutes, Miaoli, Taiwan.
ORCID-Profile: Chun-Hsien Chao, Yi-Ju Chen
Förderung
- Ministry of Science and Technology, Taiwan
Zitieren
APA
Chao, C. H., Wu, C. Y., Chou, F. L., & Chen, Y. J. (2024). Methotrexate did not add skin cancer risk in patients with psoriasis receiving narrowband ultraviolet B phototherapy: a nationwide retrospective cohort study. Clinical and Experimental Dermatology. https://doi.org/10.1093/ced/llad424
Vancouver
Chao CH, Wu CY, Chou FL, Chen YJ. Methotrexate did not add skin cancer risk in patients with psoriasis receiving narrowband ultraviolet B phototherapy: a nationwide retrospective cohort study. Clinical and Experimental Dermatology. 2024. doi:10.1093/ced/llad424
BibTeX
@article{Chao2024,
author = {Chao, Chun-Hsien and Wu, Chun-Ying and Chou, Fan-Ling and Chen, Yi-Ju},
title = {Methotrexate did not add skin cancer risk in patients with psoriasis receiving narrowband ultraviolet B phototherapy: a nationwide retrospective cohort study},
journal = {Clinical and Experimental Dermatology},
year = {2024},
doi = {10.1093/ced/llad424}
}
EUVIMED